论文部分内容阅读
Stiefel公司宣布FDA已批准其0.005%卡泊三烯(calcipotriene,Sorilux)泡沫剂用于治疗18岁以上轻中度斑块状银屑病。卡泊三烯是维生素D3类似物,具有抑制角质形成、促进细胞分化成熟及抑制炎症反应等药理作用。
Stiefel Inc. announced that FDA has approved its 0.005% calcipotriene (Sorilux) foam for the treatment of mild to moderate plaque psoriasis over the age of 18 years. Carbotriptine is a vitamin D3 analog, with the inhibition of keratinocytes, promote cell differentiation and maturation and inhibit the inflammatory response and other pharmacological effects.